BG102214A - Derivatives of azetidinons for the treatment of atherosclerosis - Google Patents
Derivatives of azetidinons for the treatment of atherosclerosisInfo
- Publication number
- BG102214A BG102214A BG102214A BG10221498A BG102214A BG 102214 A BG102214 A BG 102214A BG 102214 A BG102214 A BG 102214A BG 10221498 A BG10221498 A BG 10221498A BG 102214 A BG102214 A BG 102214A
- Authority
- BG
- Bulgaria
- Prior art keywords
- alkyl
- optionally
- aryl
- value
- whichcan
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
- C07D205/085—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams with a nitrogen atom directly attached in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
- C07D205/09—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams with a sulfur atom directly attached in position 4
- C07D205/095—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams with a sulfur atom directly attached in position 4 and with a nitrogen atom directly attached in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Abstract
The azetidinon compounds are inhibitors of the LpPLA2 enzymeand can find application for the treatment of atherosclerosis.They have the formulawhere R1 & R2 which can be the same or different, are selectedseparately from hydrogen, halogen or C(1-8) alkyl; R4 & R5 whichcan be the same or different, are selected separately fromhydrogen, C(1-6)alkyl, C(2-6) alkenyl, aryl, aryl C(1-4)alkyl andheteroaryl C(1-4)alkyl, each of which can optionally besubstituted, or R4 & R5 can be bound together forming theremaining part of C(3-7) gycloalkyl ring; X is direct bond; thegroup X1(CH2)m where X1 is CO, CONR6, COO, CONR6CO or CONR60,where R6 is hydrogen or (C1-C6) alkyl and m has the value of 0 oris multiple having the value of from 1 to 12; the group (X1)aX2,where a has the value of 0 or 1, and X2 is C(1-12) alkylene chain,broken and/or discontinued in neighbourhood with Y by one or moreX3 groups selected from 0, S(0)x, NR6, alkene or alkyn group,where x has the value of 0, 1 or 2 or the C(1-12) alkylene chain,optionally discontinued by X1; Y is optionally substituted arylgroup; Z is oxygen, and R3 is C(1-8) alkyl, C(3-8) cycloalkyl,C(3-8) cyclo-alkyl C(1-6) alkyl, heteroalkyl,heteroalkyl-C(1-4)alkyl, aryl or aryl C(1-4)alkyl, each of whichcan optionally be substituted, or Z is S(0)n where n has the valueof 0, 1 or 2, and R3 is heteroaryl or heteroaryl C(1-4)alkyl, eachof which can optionally be substututed.22 claims
Applications Claiming Priority (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9513442.5A GB9513442D0 (en) | 1995-07-01 | 1995-07-01 | Novel compounds |
GBGB9515056.1A GB9515056D0 (en) | 1995-07-22 | 1995-07-22 | Novel compounds |
GBGB9515206.2A GB9515206D0 (en) | 1995-07-25 | 1995-07-25 | Novel compounds |
GBGB9516985.0A GB9516985D0 (en) | 1995-08-18 | 1995-08-18 | Novel compounds |
GBGB9525132.8A GB9525132D0 (en) | 1995-12-08 | 1995-12-08 | Novel compounds |
GBGB9608650.9A GB9608650D0 (en) | 1996-04-26 | 1996-04-26 | Novel compounds |
GBGB9608651.7A GB9608651D0 (en) | 1996-04-26 | 1996-04-26 | Novel compounds |
PCT/EP1996/002765 WO1997002242A1 (en) | 1995-07-01 | 1996-06-20 | Azetidinone derivatives for the treatment of atherosclerosis |
Publications (1)
Publication Number | Publication Date |
---|---|
BG102214A true BG102214A (en) | 1998-08-31 |
Family
ID=27562921
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BG102214A BG102214A (en) | 1995-07-01 | 1998-01-28 | Derivatives of azetidinons for the treatment of atherosclerosis |
Country Status (23)
Country | Link |
---|---|
EP (1) | EP0840725A1 (en) |
JP (1) | JP2002515852A (en) |
KR (1) | KR19990028630A (en) |
CN (1) | CN1197452A (en) |
AP (1) | AP728A (en) |
AU (1) | AU708032B2 (en) |
BG (1) | BG102214A (en) |
BR (1) | BR9609445A (en) |
CA (1) | CA2225627A1 (en) |
CZ (1) | CZ422197A3 (en) |
EA (1) | EA199800109A1 (en) |
HU (1) | HUP9901153A3 (en) |
IL (1) | IL122650A0 (en) |
MA (1) | MA23922A1 (en) |
MX (1) | MX9800186A (en) |
NO (1) | NO976158L (en) |
NZ (1) | NZ311684A (en) |
OA (1) | OA10648A (en) |
PE (1) | PE8998A1 (en) |
PL (1) | PL324240A1 (en) |
SK (1) | SK178497A3 (en) |
TR (1) | TR199701762T1 (en) |
WO (1) | WO1997002242A1 (en) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2000502079A (en) * | 1995-12-08 | 2000-02-22 | スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー | Monocyclic .BETA.-lactam derivatives for the treatment of atherosclerosis |
GB9608649D0 (en) * | 1996-04-26 | 1996-07-03 | Smithkline Beecham Plc | Novel compounds |
EP0915843A1 (en) * | 1996-04-26 | 1999-05-19 | Smithkline Beecham Plc | Azetidinone derivatives for the treatment of atheroscleroses |
DE60139429D1 (en) * | 2000-02-16 | 2009-09-10 | Smithkline Beecham Plc | Pyrimidine-5-onderivatives as LDL-PLA2 inhibitors |
GB0024808D0 (en) | 2000-10-10 | 2000-11-22 | Smithkline Beecham Plc | Novel compounds |
US8962633B2 (en) | 2007-05-11 | 2015-02-24 | Thomas Jefferson University | Methods of treatment and prevention of metabolic bone diseases and disorders |
CN101687009A (en) | 2007-05-11 | 2010-03-31 | 宾夕法尼亚大学理事会 | Methods of treatment of skin ulcers |
EA200971050A1 (en) | 2007-05-11 | 2010-06-30 | Томас Джефферсон Юниверсити | METHODS OF TREATMENT AND PREVENTION OF NEURODEGENERATIVE DISEASES AND DISORDERS |
TW201307324A (en) | 2010-12-06 | 2013-02-16 | Glaxo Group Ltd | Compounds |
EP2651403B1 (en) | 2010-12-17 | 2020-12-02 | Glaxo Group Limited | Use of lp-pla2 inhibitors in the treatment and prevention of eye diseases |
EP2725024A4 (en) | 2011-06-27 | 2014-12-03 | Shanghai Inst Materia Medica | Azole heterocyclic compound, preparation method, pharmaceutical composition and use |
BR112014001665A2 (en) | 2011-07-27 | 2017-02-14 | Glaxo Group Ltd | 2,3-dihydroimidazo [1,2-c] pyrimidin-5 (1h) -one compounds used as lp-plaz inhibitors |
TW201321382A (en) | 2011-07-27 | 2013-06-01 | Glaxo Group Ltd | Compounds |
CA2899143A1 (en) | 2013-01-25 | 2014-07-31 | Glaxosmithkline Intellectual Property Development Limited | Bicyclic pyrimidone compounds as inhibitors of lp-pla2 |
WO2014114248A1 (en) | 2013-01-25 | 2014-07-31 | Glaxosmithkline Intellectual Property Development Limited | Compounds |
EP2948452B1 (en) | 2013-01-25 | 2017-08-09 | GlaxoSmithKline Intellectual Property Development Limited | 2,3-dihydroimidazol[1,2-c]pyrimidin-5(1h)-one based lipoprotein-associated phospholipase a2 (lp-pla2) inhibitors |
WO2016012917A1 (en) | 2014-07-22 | 2016-01-28 | Glaxosmithkline Intellectual Property Development Limited | 1,2,3,5-tetrahydroimidazo[1,2-c]pyrimidine derivatives useful in the treatment of diseases and disorders mediated by lp-pla2 |
WO2016012916A1 (en) | 2014-07-22 | 2016-01-28 | Glaxosmithkline Intellectual Property Development Limited | 1,2,3,5-tetrahydroimidazo[1,2-c]pyrimidine derivatives useful in the treatment of diseases and disorders mediated by lp-pla2 |
CN112778331B (en) | 2019-11-09 | 2022-07-05 | 上海赛默罗生物科技有限公司 | Tricyclic dihydroimidazopyrimidinone derivatives, preparation method, pharmaceutical composition and application thereof |
CN115304620A (en) | 2021-05-07 | 2022-11-08 | 上海赛默罗生物科技有限公司 | Pyrimidone derivatives, preparation method, pharmaceutical composition and application thereof |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4680391A (en) * | 1983-12-01 | 1987-07-14 | Merck & Co., Inc. | Substituted azetidinones as anti-inflammatory and antidegenerative agents |
NZ228600A (en) * | 1988-04-11 | 1992-02-25 | Merck & Co Inc | 1-(benzylaminocarbonyl)-4-phenoxy-azetidin-2-one derivatives |
IL99658A0 (en) * | 1990-10-15 | 1992-08-18 | Merck & Co Inc | Substituted azetidinones and pharmaceutical compositions containing them |
GB9421816D0 (en) * | 1994-10-29 | 1994-12-14 | Smithkline Beecham Plc | Novel compounds |
SK80397A3 (en) * | 1994-12-22 | 1998-01-14 | Smithkline Beecham Plc | Substituted azetidin-2-ones, preparation method thereof, farmaceutical compositions and their use |
-
1996
- 1996-06-20 SK SK1784-97A patent/SK178497A3/en unknown
- 1996-06-20 BR BR9609445A patent/BR9609445A/en unknown
- 1996-06-20 CA CA002225627A patent/CA2225627A1/en not_active Abandoned
- 1996-06-20 PL PL96324240A patent/PL324240A1/en unknown
- 1996-06-20 NZ NZ311684A patent/NZ311684A/en unknown
- 1996-06-20 WO PCT/EP1996/002765 patent/WO1997002242A1/en not_active Application Discontinuation
- 1996-06-20 JP JP50477297A patent/JP2002515852A/en active Pending
- 1996-06-20 IL IL12265096A patent/IL122650A0/en unknown
- 1996-06-20 KR KR1019970709952A patent/KR19990028630A/en not_active Application Discontinuation
- 1996-06-20 CZ CZ974221A patent/CZ422197A3/en unknown
- 1996-06-20 EP EP96922030A patent/EP0840725A1/en not_active Withdrawn
- 1996-06-20 HU HU9901153A patent/HUP9901153A3/en unknown
- 1996-06-20 AU AU63050/96A patent/AU708032B2/en not_active Ceased
- 1996-06-20 TR TR97/01762T patent/TR199701762T1/en unknown
- 1996-06-20 EA EA199800109A patent/EA199800109A1/en unknown
- 1996-06-20 AP APAP/P/1997/001161A patent/AP728A/en active
- 1996-06-20 CN CN96196661A patent/CN1197452A/en active Pending
- 1996-06-28 PE PE1996000496A patent/PE8998A1/en not_active Application Discontinuation
- 1996-06-28 MA MA24298A patent/MA23922A1/en unknown
-
1997
- 1997-12-30 NO NO976158A patent/NO976158L/en unknown
- 1997-12-31 OA OA70172A patent/OA10648A/en unknown
-
1998
- 1998-01-07 MX MX9800186A patent/MX9800186A/en unknown
- 1998-01-28 BG BG102214A patent/BG102214A/en unknown
Also Published As
Publication number | Publication date |
---|---|
AP9701161A0 (en) | 1998-01-31 |
MX9800186A (en) | 1998-07-31 |
EA199800109A1 (en) | 1998-10-29 |
HUP9901153A3 (en) | 1999-11-29 |
IL122650A0 (en) | 1998-08-16 |
CN1197452A (en) | 1998-10-28 |
SK178497A3 (en) | 1998-07-08 |
NZ311684A (en) | 2000-04-28 |
EP0840725A1 (en) | 1998-05-13 |
WO1997002242A1 (en) | 1997-01-23 |
TR199701762T1 (en) | 1998-05-21 |
PE8998A1 (en) | 1998-03-20 |
CZ422197A3 (en) | 1998-06-17 |
AU708032B2 (en) | 1999-07-29 |
NO976158L (en) | 1998-02-25 |
OA10648A (en) | 2002-09-25 |
JP2002515852A (en) | 2002-05-28 |
KR19990028630A (en) | 1999-04-15 |
BR9609445A (en) | 1999-04-06 |
NO976158D0 (en) | 1997-12-30 |
PL324240A1 (en) | 1998-05-11 |
AP728A (en) | 1999-01-29 |
HUP9901153A2 (en) | 1999-08-30 |
AU6305096A (en) | 1997-02-05 |
CA2225627A1 (en) | 1997-01-23 |
MA23922A1 (en) | 1996-12-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BG102214A (en) | Derivatives of azetidinons for the treatment of atherosclerosis | |
TW359670B (en) | Process for producing quinazolin-4-one derivatives | |
EP0760657A4 (en) | Novel potent inducers of terminal differentiation and methods of use thereof | |
KR950700894A (en) | Taxol derivatives | |
TR199800011T1 (en) | Benzo$g] quinoline t�revleri | |
ATE27810T1 (en) | 2-(3-IOD-2-PROPINYLOXY)-ETHANOL CARBAMATS, THEIR PRODUCTION AND USE AS ANTIMICROBIAL SUBSTANCES. | |
ES2134815T3 (en) | NEW POWERFUL INDUCTORS OF TERMINAL DIFFERENTIATION AND METHODS FOR USING THEM. | |
TR199701173T1 (en) | New arylglycinamide derivatives, method for their preparation. | |
TR199802160T2 (en) | Azetidinone derivatives for the treatment of atherosclerosis. | |
EA200000431A2 (en) | New substituted dimeric compounds, a process for their preparation and pharmaceutical compositions containing them | |
BR1100061A (en) | Compound, process for its preparation, composition and use | |
MX9706394A (en) | 1-aryl-2-acylamino-ethane compounds and their use as neurokinin especially neurokinin 1 antagonists. | |
HU9402444D0 (en) | Diacyl-substituted guanidine derivatives, process for producing them and pharmaceutical compositions containing them | |
TW334425B (en) | Annelated dihydropyridines for preparing pharmaceutical preparations | |
TW238304B (en) | A process for the preparation of 1-substituted-5(4H)-tetrazolinones | |
GR3023757T3 (en) | Cyclic benzylamino, benzylamido and benzylimido derivatives as antipsychotic agents. | |
DE69526097D1 (en) | BICYCLIC CARBOXAMIDES AS 5-HT1A RECEPTOR LIGANDS | |
PE68299A1 (en) | 1,2,3,4-THERAPEUTIC TETRAHYDROISOKINOLINS | |
GB9612600D0 (en) | Chemical compounds | |
RU98112496A (en) | 5-NAPHTALIN-1-IL-1,3-DIOXANA DERIVATIVES, THEIR PRODUCTION AND THERAPEUTIC USE | |
DE69810294T2 (en) | CALIXAREN TUBES AS CATION RECEPTORS | |
MX9804482A (en) | Quinolines and quinazolines useful in therapy. | |
ES2056025A1 (en) | New indole derivatives | |
EP0165032A3 (en) | Dihydropyridine anti-ischaemic and antihypertensive agents |